{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:29:43Z","timestamp":1794018583477,"version":"4.8.0"},"reference-count":15,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"25","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>\n                    CARTITUDE-1 evaluated ciltacabtagene autoleucel (cilta-cel) in patients with heavily pretreated relapsed\/refractory multiple myeloma (RRMM). We describe overall survival (OS), \u22655-year progression-free outcomes, associated biomarkers, and safety, with a median study follow-up of 61.3 months. For the 97 treated patients, median OS was 60.7 months (95% CI, 41.9 to not estimable). One third (32\/97) of patients remain alive and progression-free for \u22655 years after a single cilta-cel infusion, without maintenance treatment. Twelve of these patients treated at a single center underwent serial minimal residual disease (MRD) and positron emission tomography-computed tomography assessments, and all (100%) were MRD-negative (at least 10\n                    <jats:sup>\u22125<\/jats:sup>\n                    threshold) and imaging-negative at year 5 or later after cilta-cel. Baseline characteristics, including the presence of high-risk cytogenetics and extramedullary disease, were generally comparable for the 32 patients who were progression-free for \u22655 years versus patients who had progressive disease by year 5. A trend of lower baseline tumor burden, higher fraction of na\u00efve T-cells in the cilta-cel drug product, higher T cell-to-neutrophil ratio, higher hemoglobin and platelets at baseline, and higher effector-to-target ratio were associated with \u22655-year progression-free status. The safety profile of cilta-cel remained consistent with previous reports. To our knowledge, our data provide the first evidence that cilta-cel is potentially curative in patients with RRMM.\n                  <\/jats:p>","DOI":"10.1200\/jco-25-00760","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T08:00:14Z","timestamp":1748937614000},"page":"2766-2771","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":160,"title":["Long-Term (\u22655-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1200","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct03548207","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-6518","authenticated-orcid":true,"given":"Sundar","family":"Jagannath","sequence":"first","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Martin","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":true,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-3843","authenticated-orcid":true,"given":"Adam D.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3066-1275","authenticated-orcid":true,"given":"Noopur","family":"Raje","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myo","family":"Htut","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0947-8871","authenticated-orcid":true,"given":"Abhinav","family":"Deol","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Institute, Wayne State University, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2275-7544","authenticated-orcid":true,"given":"Mounzer","family":"Agha","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4362-0376","authenticated-orcid":true,"given":"Jesus G.","family":"Berdeja","sequence":"additional","affiliation":[{"name":"Tennessee Oncology, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Lesokhin","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8014-706X","authenticated-orcid":true,"given":"Jessica J.","family":"Liegel","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Bone Marrow Transplantation, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9914-5628","authenticated-orcid":true,"given":"Adriana","family":"Rossi","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5462-4991","authenticated-orcid":true,"given":"Alex","family":"Lieberman-Cribbin","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5484-8731","authenticated-orcid":true,"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4377-9742","authenticated-orcid":true,"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9694-8469","authenticated-orcid":true,"given":"Samir","family":"Parekh","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6576-7240","authenticated-orcid":true,"given":"Rocio","family":"Montes de Oca","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki","family":"Plaks","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huabin","family":"Sun","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnob","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Schecter","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoletta","family":"Lendvai","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepu","family":"Madduri","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Lengil","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieqing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Legend Biotech USA Inc, Somerset, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mythili","family":"Koneru","sequence":"additional","affiliation":[{"name":"Legend Biotech USA Inc, Somerset, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Akram","sequence":"additional","affiliation":[{"name":"Legend Biotech USA Inc, Somerset, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Patel","sequence":"additional","affiliation":[{"name":"Legend Biotech USA Inc, Somerset, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octavio","family":"Costa Filho","sequence":"additional","affiliation":[{"name":"Legend Biotech USA Inc, Somerset, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2597-6822","authenticated-orcid":true,"given":"Andrzej J.","family":"Jakubowiak","sequence":"additional","affiliation":[{"name":"University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1661-718X","authenticated-orcid":true,"given":"Peter M.","family":"Voorhees","sequence":"additional","affiliation":[{"name":"Atrium Health\/Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_10_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02404-6"},{"key":"e_1_3_10_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-144387"},{"key":"e_1_3_10_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_3_10_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842"},{"key":"e_1_3_10_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"e_1_3_10_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)02346-2"},{"key":"e_1_3_10_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8009"},{"key":"e_1_3_10_9_2","unstructured":"US Food and Drug Administration: FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma [press release] 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma"},{"key":"e_1_3_10_10_2","volume-title":"CARVYKTI (Ciltacabtagene Autoleucel) [prescribing information]","year":"2023","unstructured":"CARVYKTI (Ciltacabtagene Autoleucel) [prescribing information]. Horsham, PA, Janssen Biotech Inc, 2023"},{"key":"e_1_3_10_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014097"},{"key":"e_1_3_10_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-182298"},{"key":"e_1_3_10_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-188310"},{"key":"e_1_3_10_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07503-y"},{"key":"e_1_3_10_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-201533"},{"key":"e_1_3_10_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01530-z"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-00760","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T21:59:22Z","timestamp":1756331962000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-00760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":15,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1200\/JCO-25-00760"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-00760","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2025-04-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}